Page 73 - Read Online

Harada et al. J Cancer Metastasis Treat 2018;4:18 I http://dx.doi.org/10.20517/2394-4722.2017.74 Page 7 of 10

is expected. Treatment strategies for metastatic GAC with HER2 negative is two-drug cytotoxic regimen; a
platinum compound and a fluoropyrimidine. For GAC with HER2 positive, trastuzumab should be added.
Metastatic GAC should be treated based on global trial [Table 3].

DECLARATIONS
Authors’ contributions
Conception and design: Harada K, Ajani JA
Acquisition of data: Harada K
Manuscript writing: Harada K, Baba H, Ajani JA
Final approval of manuscript: Harada K, Baba H, Ajani JA

Financial support and sponsorship
This research was supported by generous grants from the Caporella, Dallas, Sultan, Park, Smith, Frazier,
Oaks, Vanstekelenberg, Planjery, and Cantu families, as well as from the Schecter Private Foundation,
Rivercreek Foundation, Kevin Fund, Myer Fund, Dio Fund, Milrod Fund, and The University of Texas
MD Anderson Cancer Center (Houston, Texas, USA) multidisciplinary grant program. This research was
also supported in part by the National Cancer Institute and Department of Defense awards CA129906.
CA 127672, CA138671, and CA172741 and the DOD grants: CA150334 and CA162445 (J.A.A.), and by a
grant from the Japan Society for the Promotion of Science Overseas Research Fellowships and Program for
Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers (K.H.).

Conflicts of interest
The authors declare that they have no conflicts of interest.

Patient consent
Not applicable.

Ethics approval
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS,
Feuer EJ, Cronin KA (editors). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Based on November 2016 SEER
data submission, posted to the SEER web site, April 2017. Available from: https://seer.cancer.gov/csr/1975_2014/ [Last accessed on 10
Apr 2018]
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA
1991;265:1287-9.
3. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
4. Elimova E, Ajani JA. Surgical resection first for localized gastric adenocarcinoma: are there adjuvant options? J Clin Oncol
2015;33:3085-91.
5. Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS,
Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani
JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and
effectiveness of surveillance. Oncotarget 2017;8:81430-40.
6. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM,
Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal
junction. N Engl J Med 2001;345:725-30.
7. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM,